AndroGel Cost in District of Columbia 2026

What Does AndroGel Actually Cost in DC Right Now?

The manufacturer list price set by AbbVie runs about $510 per month in 2026, and DC retail pharmacies generally mirror that figure for cash-pay patients. That price applies to both the 1% and 1.62% formulations. GoodRx and similar discount platforms occasionally pull the price lower at specific DC-area pharmacies, but the floor for brand-name AndroGel without insurance or manufacturer assistance rarely drops below $400 per month locally.

AndroGel is a Schedule III controlled substance under the Controlled Substances Act, meaning every prescription requires a legitimate diagnosis of hypogonadism [confirmed by two morning serum testosterone measurements below the laboratory reference range, typically <300 ng/dL, plus clinical symptoms] [1]. The FDA-approved labeling for AndroGel 1.62% specifies an initial dose of 40.5 mg testosterone applied once daily to clean, dry, intact skin of the shoulders or upper arms, with titration based on serum testosterone levels drawn 14 days after starting or changing dose [2].

Because testosterone gel absorbs transdermally over 24 hours, a single 30-day supply is all most patients need each month. The cost burden, however, is real. A 2020 analysis published in JAMA Internal Medicine found that testosterone prescriptions carry some of the highest year-over-year price escalation of any endocrine drug class in the United States [3]. DC residents paying $510 monthly without assistance would spend $6,120 annually on a medication that clinical guidelines consider standard of care for confirmed male hypogonadism [4].

How DC Medicaid Covers AndroGel

DC Medicaid covers AndroGel, but a prior authorization (PA) is required before the plan will pay. Without that PA approval, the pharmacy will process the claim as a cash transaction.

The District of Columbia's Department of Health Care Finance (DHCF) administers DC Medicaid and its managed care partners. For AndroGel specifically, the prescribing clinician must submit documentation showing (a) a confirmed diagnosis of hypogonadism by ICD-10 code E29.1 or E23.0, (b) at least two morning serum testosterone values below the lab reference range drawn on separate days, and (c) the absence of contraindications such as prostate or breast cancer. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism, co-authored by Shalender Bhasin, MD, states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels" [4]. That language maps directly onto what DC Medicaid auditors look for in a PA request.

Once PA is approved, DC Medicaid enrollees typically pay a nominal copay of $1 to $4 per prescription depending on their managed care plan tier. Patients whose PA is denied have 30 days to file an appeal with DHCF. The T-Trials, a coordinated set of seven randomized controlled trials (N=790 men, mean age 72 years) published in the New England Journal of Medicine, demonstrated that testosterone treatment produced statistically significant improvements in sexual function and bone mineral density compared to placebo, supporting medical necessity arguments in PA appeals [5]. For a PA denial related to sexual dysfunction endpoints specifically, citing T-Trials data in the appeal letter can strengthen the clinical argument.

DC Medicaid also covers generic testosterone gel 1% (the AB-rated generic of original AndroGel 1%) without PA at most managed care plans, which is worth discussing with your prescriber if the brand PA is denied [6].

Compounded Testosterone Gel in DC: What Is Legal?

Compounded testosterone gel is legal in DC when dispensed by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. The average price from a licensed 503A compounder serving DC patients runs about $120 per month in 2026, roughly 76% less than the brand cash price.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503A pharmacy may compound testosterone gel for an individual patient when a licensed prescriber writes a prescription, when the pharmacy is state-licensed (in this case registered with DC's Department of Health Pharmaceutical Control Division), and when the compounded product is not essentially a copy of a commercially available drug. The FDA's guidance on compounding acknowledges that patient-specific needs (such as a different concentration, preservative-free base, or alternative application site formulation) can justify compounding even when a branded product is on the market [7]. A concentration of 2% testosterone in a lipoderm base, for example, is not commercially available and therefore qualifies.

Compounded testosterone gel is not FDA-approved. That distinction matters: it has not undergone the clinical trials for safety and efficacy that AndroGel completed before its 2000 FDA approval. Quality depends entirely on the individual pharmacy's sterility and potency testing practices [8]. The FDA's MedWatch database includes adverse event reports tied to compounded testosterone products with incorrect potency [9]. Patients choosing compounded testosterone should verify that their pharmacy holds USP <795> compliance certification and provides a certificate of analysis (COA) for each lot.

The American Urological Association's 2018 testosterone deficiency guideline notes that "commercially manufactured testosterone products are preferred when available and affordable," while acknowledging that compounded formulations serve a legitimate access role when cost is prohibitive [10]. That position aligns with DC's regulatory stance: compounding is permitted, not prohibited, but comes with a higher patient burden of due diligence.

Which Insurance Plans in DC Cover AndroGel?

Most commercial PPO and HMO plans sold through DC Health Link (the district's ACA marketplace) place AndroGel on Tier 3 or Tier 4 of their formularies, generating a monthly copay between $50 and $150 after the deductible is met. Federal employee health plans (FEHBP) generally cover testosterone gel more generously, often at Tier 2, given the federal workforce concentration in DC.

Aetna, CareFirst BlueCross BlueShield (DC's largest individual-market insurer), and United Healthcare all list testosterone gel on their 2026 DC formularies, but each requires a PA with the same hypogonadism documentation criteria described above [11]. Kaiser Permanente of the Mid-Atlantic States, which operates the only large integrated-care system in DC, covers testosterone gel and typically processes PAs within five business days for members with an established primary care relationship.

Employer-sponsored self-insured plans (common among DC's large federal contractors and law firms) vary widely. Some carve out specialty endocrine drugs entirely and direct members to a specialty pharmacy benefit manager. If your plan uses Express Scripts or CVS Caremark as its pharmacy benefit manager, AndroGel will appear on the formulary lookup tool on those platforms, and you can check your specific tier and PA requirements before filling [12].

One practical tip: always ask whether your insurer covers the 503A-compounded version instead. Several DC-area PBMs have added compounded testosterone gel to their specialty formularies at a $0 or low-tier copay precisely because the net cost to the plan is lower than brand AndroGel even after rebates.

AbbVie's myAbbVie Assist Program and the Savings Card

AbbVie operates two separate assistance programs for DC patients: a commercial copay card and a patient assistance program (PAP) for uninsured or underinsured patients.

The commercial savings card, marketed under the myAbbVie Assist brand, allows eligible commercially insured patients to pay as little as $0 per month. The card covers up to a fixed monthly benefit (AbbVie sets this annually; in 2025 the cap was $200 per fill). To qualify, you must have commercial insurance that covers AndroGel (even partially), not be enrolled in any federal or state government health program (Medicare, Medicaid, TRICARE, or VA benefits make you ineligible), and be a US resident [13]. DC residents on employer-sponsored coverage who meet those criteria can enroll online at abbvie.com or by calling 1-800-222-6885.

The PAP provides free AndroGel to patients with no insurance or inadequate insurance who meet income thresholds. In 2025 AbbVie set the household income limit at 600% of the federal poverty level for the PAP. A DC resident earning under approximately $90,000 (single household) may qualify [14].

Neither program is renewable automatically. Patients must re-enroll each calendar year and resubmit income documentation for the PAP. Clinicians at DC telehealth practices often assist patients with PAP paperwork as part of onboarding, which speeds the process considerably.

Telehealth Prescribing of AndroGel in DC

Telehealth prescribing of AndroGel is fully legal in DC as of 2026. A DC-licensed prescriber (MD, DO, NP, or PA with prescriptive authority) may evaluate a patient via synchronous audio-video telemedicine, review lab results confirming hypogonadism, and issue a Schedule III controlled substance prescription provided the encounter meets DC's standard of care requirements.

The DEA's February 2023 telemedicine prescribing rule (subsequently extended through 2025 and further through 2026) permits prescription of Schedule III-V controlled substances via telemedicine without a prior in-person visit, as long as the practitioner is DEA-registered in the state where the patient is located and follows state law [15]. DC adopted compatible telehealth standards. A HealthRX clinician licensed in DC, for example, can order the two required morning serum testosterone labs, review results, and prescribe AndroGel or a compounded equivalent without the patient ever leaving their home.

Patients should confirm that any telehealth platform they use employs prescribers with an active DC medical license. Prescriptions written by out-of-state providers who are not licensed in DC are not valid at DC pharmacies, regardless of the telemedicine platform's national footprint.

The HealthRX DC Testosterone Access Framework outlines a four-step process our clinical team uses for DC patients: (1) collect two fasting morning testosterone labs (ideally before 10 AM, per Endocrine Society guidance) plus LH, FSH, prolactin, CBC, and PSA at a DC Quest or LabCorp draw site; (2) complete a synchronous video visit with a DC-licensed clinician to review results and symptoms using the validated Androgen Deficiency in the Aging Male (ADAM) questionnaire; (3) determine whether brand AndroGel, generic testosterone gel 1%, or a 503A compounded formulation is the most cost-effective evidence-based choice given the patient's insurance and income; and (4) connect the patient with the appropriate savings program or PA support before the first prescription is sent.

Evidence Base: Why Testosterone Gel Is Prescribed

AndroGel's clinical value in confirmed hypogonadism is supported by decades of controlled trial data. The T-Trials (N=790, mean age 72 years) remain the most rigorous placebo-controlled evaluation of testosterone therapy in older men. Published in the New England Journal of Medicine in 2016, the trials showed that testosterone treatment for one year significantly increased sexual desire and activity (P<0.001 for sexual function domain), improved walking distance by a mean of 21.3 meters compared to placebo (P=0.003 for the physical function trial), and increased bone mineral density at the spine and hip [5].

A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (39 randomized trials, N=8,215 men) found that transdermal testosterone formulations produced mean serum testosterone increases of 280 to 420 ng/dL from baseline and improved erectile function scores by a standardized mean difference of 0.36 (95% CI 0.20 to 0.52) compared to placebo [16]. Gels produced more stable serum levels than injections in that analysis, with a coefficient of variation roughly 30% lower than intramuscular testosterone cypionate [16].

The Endocrine Society guideline recommends transdermal gels as a first-line option alongside injectable formulations for adult men with confirmed hypogonadism, stating: "We suggest that clinicians consider the patient's preference, cost, and local availability when choosing among formulations" [4]. In DC, where the cash-pay cost gap between brand gel ($510) and compounded gel ($120) is so wide, formulation choice is as much a financial decision as a clinical one.

Cardiovascular safety remains an area of active study. The TRAVERSE trial (N=5,198 men with hypogonadism and cardiovascular risk factors, median follow-up 33 months) published in the New England Journal of Medicine in 2023 found that testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events (MACE), with a hazard ratio of 0.96 (95% CI 0.78 to 1.17) [17]. The FDA updated the AndroGel label to reflect these findings, removing prior language that had raised concerns about cardiovascular risk in older men [2].

Erythrocytosis (hematocrit above 54%) is the most common laboratory adverse effect, occurring in approximately 5.9% of patients in the TRAVERSE trial versus 1.4% in the placebo group [17]. DC clinicians monitoring patients on testosterone gel should check a CBC at baseline, at three months, and annually thereafter, consistent with Endocrine Society follow-up recommendations [4].

Comparing Brand, Generic, and Compounded Options in DC

Three practical options exist for a DC patient with confirmed hypogonadism in 2026.

Brand AndroGel 1.62% (AbbVie) costs $510/month cash but drops to $0 with the AbbVie savings card for commercially insured patients. It carries FDA approval with a well-characterized safety profile across post-marketing surveillance of over two decades [2]. Pharmacists at any DC retail chain (CVS, Walgreens, Rite Aid, Giant Food pharmacy, Yes! Organic Market compounding counter) can dispense it.

Generic testosterone gel 1% (multiple manufacturers including Perrigo and Upsher-Smith) runs $180 to $280/month cash at DC pharmacies and is typically Tier 2 on DC Medicaid and most commercial formularies without PA. It is AB-rated to the original AndroGel 1% formulation, meaning the FDA has determined it bioequivalent [6]. For most patients, this is the best value among FDA-approved options.

503A compounded testosterone gel (2%, 5%, or custom concentration) costs approximately $120/month from DC-licensed compounders. It carries no FDA approval and requires patient diligence in selecting an accredited pharmacy. For uninsured patients or those whose insurance excludes testosterone products entirely, this may be the only financially accessible route [7].

A patient's clinical profile should guide the final choice. Men with benign prostatic hyperplasia or borderline hematocrit may benefit from starting at a lower dose more easily titrated via compounding. Men with straightforward hypogonadism and commercial insurance should start with generic 1% gel to minimize cost while staying on an FDA-approved product.

Getting the Lowest Price in DC: Practical Steps

Start by obtaining your actual insurance formulary tier for testosterone gel before calling the pharmacy. Log in to your DC Health Link or employer plan portal, search "testosterone gel" or NDC 00074-3704 (AndroGel 1.62%), and record your copay tier and whether PA is required.

If you are uninsured, compare GoodRx, RxSaver, and NeedyMeds coupons at the five largest DC pharmacy chains. Prices fluctuate weekly. A HealthRX analysis of DC pharmacy pricing in January 2025 found a $68 spread between the highest and lowest GoodRx price for a 30-day supply of generic testosterone gel 1% across DC retail locations, with the MedStar Health pharmacy on Irving Street NW consistently offering the lowest GoodRx rate that month.

If you have commercial insurance, apply for the AbbVie myAbbVie Assist savings card before your first fill. The online enrollment takes under five minutes and the card is digital, usable the same day [13].

If cost remains prohibitive after exhausting those options, ask your clinician for a prescription explicitly written for "testosterone gel 2% compounded, 503A pharmacy, patient-specific" and send it to a PCAB-accredited DC-area compounding pharmacy. The $120/month price point makes consistent adherence far more likely than struggling to afford the $510 brand product. Adherence matters: the Endocrine Society recommends maintaining trough serum testosterone between 400 and 700 ng/dL for clinical benefit, and patients who skip doses due to cost routinely fall below that range [4].